ALN-TTRSC02-007
Brief description of study
This is a multicenter,Phase 3b open-label extension study to evaluate the safety, efficacy of 25 mg subcutaneous vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who are actively participating in the patisiran parent studies HELIOS B, APOLLO B and Patisiran EAP. Subjects will receive 25 mg of Vutrisiran SQ every 3 months from 6 months up to 36 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
